CO4900058A1 - Terapia de combinacion para el tratamiento de psicosis - Google Patents

Terapia de combinacion para el tratamiento de psicosis

Info

Publication number
CO4900058A1
CO4900058A1 CO97054849A CO97054849A CO4900058A1 CO 4900058 A1 CO4900058 A1 CO 4900058A1 CO 97054849 A CO97054849 A CO 97054849A CO 97054849 A CO97054849 A CO 97054849A CO 4900058 A1 CO4900058 A1 CO 4900058A1
Authority
CO
Colombia
Prior art keywords
composition
component
olanzapine
component compound
amount
Prior art date
Application number
CO97054849A
Other languages
English (en)
Inventor
Bymaster Franklin Porter
Kenneth Wayne Perry
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4900058A1 publication Critical patent/CO4900058A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una composición farmacéutica que comprende un primer componenteque es un antipsicótico atípico y un segundo componente que es un inhibidor de la recaptación se serotonina.Una composición de la Reivindicación 8, que comprende un primer componente elegido entre el grupo compuesto por olanzapina, clozapina, risperidona, sertindol, quetiapina y ziprasidona, en combinación con un segundo componente elegido entre el grupo compuesto por fluoxetina, venlafaxina, citalopram, fluvoxamina, paroxetina, sertralina, milnacipran y duloxetina. Una composición de la Reivindicación 8 que está adaptada para la administración oral. Una composición de cualquiera de las Reivindicaciones 8, 9 ó 10, en la que el primer compuesto componente es olanzapina. Una composición de la Reivindicación 11, en la que el primer compuesto componente es olanzapina de Forma II. Una composición de cualquiera de las Reivindicaciones 8, 9, 10, 11 ó 12, en la que el segundo compuesto componente es fluoxetina o Una composición de la Reivindicación 10, en la que el primer compuesto componente es olanzapina y se encuentra en la cantidad de aproximadamente 0,25 a aproximadamente 50 mg. Una composición de la Reivindicación 10, en la que el primer compuesto componente es olanzapina y se encuentra en la cantidad de aproximadamente 1 a aproximadamente 30 mg. Una composición de la Reivindicación 10, en la que el primer compuesto componente es olanzapina y se encuentra en la cantidad de aproximadamente 1 a aproximadamente 25 mg. Una composición de la Reivindicación 10, en la que el segundo compuesto componente es fluoxetina y se encuentra en la cantidad de aproximadamente 10 a aproximadamente 40 mg. 1Una composición de la Reivindicación 10, en la que el segundo compuesto componente es fluoxetina y se encuentra en la cantidad de aproximadamente 20 a aproximadamente 80 mg.
CO97054849A 1996-09-23 1997-09-19 Terapia de combinacion para el tratamiento de psicosis CO4900058A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2688496P 1996-09-23 1996-09-23

Publications (1)

Publication Number Publication Date
CO4900058A1 true CO4900058A1 (es) 2000-03-27

Family

ID=21834363

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97054849A CO4900058A1 (es) 1996-09-23 1997-09-19 Terapia de combinacion para el tratamiento de psicosis

Country Status (30)

Country Link
US (1) US6147072A (es)
EP (1) EP0830864B9 (es)
JP (1) JP2001503031A (es)
KR (1) KR100532901B1 (es)
CN (1) CN1162156C (es)
AR (1) AR008462A1 (es)
AT (1) ATE231724T1 (es)
AU (1) AU719033C (es)
BR (1) BR9711530A (es)
CA (1) CA2264941C (es)
CO (1) CO4900058A1 (es)
CZ (1) CZ301154B6 (es)
DE (1) DE69718731T2 (es)
DK (1) DK0830864T3 (es)
EA (1) EA001317B1 (es)
EG (1) EG24660A (es)
ES (1) ES2191152T3 (es)
HK (1) HK1009755A1 (es)
HU (1) HU228178B1 (es)
IL (2) IL128730A0 (es)
MY (1) MY125564A (es)
NO (1) NO319166B1 (es)
NZ (1) NZ334168A (es)
PE (1) PE110198A1 (es)
PL (1) PL190374B1 (es)
RS (1) RS49828B (es)
TW (1) TW541178B (es)
UA (1) UA62937C2 (es)
WO (1) WO1998011897A1 (es)
ZA (1) ZA977967B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO1999055338A1 (en) * 1998-04-24 1999-11-04 Scarista Limited Treatment of depression and pharmaceutical preparations therefor
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
HUP0101901A3 (en) * 1998-05-22 2002-06-28 Lilly Co Eli Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
IL139591A0 (en) * 1998-05-29 2002-02-10 Lilly Co Eli Combination therapy for treatment of bipolar disorders
WO2000024399A1 (en) * 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
WO2000030648A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AU3810100A (en) 1999-03-12 2000-10-04 Basf Aktiengesellschaft Stable pharmaceutical application form for paroxetin anhydrate
JP2002544223A (ja) * 1999-05-12 2002-12-24 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 精神病性障害の治療方法
EP1223939A1 (en) * 1999-05-19 2002-07-24 AstraZeneca AB Method of treating weight gain
WO2000074784A1 (en) * 1999-06-09 2000-12-14 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
JP2003510266A (ja) * 1999-09-28 2003-03-18 ハー・ルンドベック・アクチエゼルスカベット 溶融顆粒化された調合物及びこの調合物から製造された、放出が調節された投薬形
WO2001043740A1 (en) 1999-12-17 2001-06-21 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
CA2411386A1 (en) * 2000-06-30 2002-01-10 Eli Lilly And Company Combination therapy for treatment of psychoses
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
UA82828C2 (en) * 2001-05-01 2008-05-26 Lundbeck & Co As H The use of enantiomeric pure escitalopram for treatment of depression
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US7973043B2 (en) * 2002-07-30 2011-07-05 Peter Migaly Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
BR0317771A (pt) 2002-12-27 2005-11-22 Otsuka Pharma Co Ltd Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
EP1633361A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Anxiety treatments with ziprasidone
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
CA2547639A1 (en) 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2007516292A (ja) * 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
US8221778B2 (en) * 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP1711124A4 (en) * 2004-01-12 2011-06-01 Univ Pennsylvania LONG-TERM RELEASE PREPARATIONS AND METHODS OF USE THEREOF
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
DE112005000641T5 (de) 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
WO2006083204A1 (en) * 2004-12-27 2006-08-10 Alpha 2 Pharmaceutical Ab Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US20070093471A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals, Llc Compositions and methods for the administration clozapine formulations which modulate body weight
JP5467870B2 (ja) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
RU2508096C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
RU2508106C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
DK2185155T3 (en) * 2007-08-03 2018-01-02 Richter Gedeon Nyrt PHARMACEUTICAL COMPOSITIONS WITH DOPAMINE RECEPTOR LIGANDS AND TREATMENT METHODS USING DOPAMINE RECEPTOR LIGANDS
JP2011510024A (ja) * 2008-01-25 2011-03-31 アルファファーム ピーティーワイ リミテッド デュロキセチンの遅延放出医薬組成物
WO2011018801A2 (en) * 2009-08-12 2011-02-17 Genepharm India Pvt Ltd Solid oral dosage form of ziprasidone
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
WO2015089494A1 (en) * 2013-12-13 2015-06-18 Ankenman Ralph Compositions and methods for treating dysregulated systems
WO2015120317A1 (en) * 2014-02-07 2015-08-13 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
SI3368534T1 (sl) 2015-10-30 2021-04-30 Neurocrine Biosciences, Inc. Valbenazin ditosilat in njegovi polimorfi
SI3394057T1 (sl) 2015-12-23 2022-06-30 Neurocrine Biosciences, Inc. Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
EA201991784A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
AU2019322863A1 (en) 2018-08-15 2021-03-11 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108938635A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种低剂量非典型抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
JP2000507544A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
US5846928A (en) * 1996-08-01 1998-12-08 Pasken Products Co., Ltd. Method for treating cancer patients
US5877198A (en) * 1996-10-17 1999-03-02 Milkhaus Laboratory, Inc. Treatment of urinary incontinence

Also Published As

Publication number Publication date
EA001317B1 (ru) 2001-02-26
ES2191152T3 (es) 2003-09-01
JP2001503031A (ja) 2001-03-06
DK0830864T3 (da) 2003-05-26
AU719033C (en) 2005-08-04
AR008462A1 (es) 2000-01-19
IL128730A0 (en) 2000-01-31
AU719033B2 (en) 2000-05-04
HUP9903905A3 (en) 2001-03-28
CZ98799A3 (cs) 1999-12-15
WO1998011897A1 (en) 1998-03-26
EP0830864B1 (en) 2003-01-29
EG24660A (en) 2010-04-07
UA62937C2 (uk) 2004-01-15
KR20000048518A (ko) 2000-07-25
NZ334168A (en) 2000-09-29
NO991381L (no) 1999-03-22
ATE231724T1 (de) 2003-02-15
YU15299A (sh) 2002-06-19
DE69718731T2 (de) 2003-09-11
NO991381D0 (no) 1999-03-22
MY125564A (en) 2006-08-30
AU4411297A (en) 1998-04-14
CN1230886A (zh) 1999-10-06
CZ301154B6 (cs) 2009-11-18
IL161833A0 (en) 2005-11-20
CN1162156C (zh) 2004-08-18
EP0830864A1 (en) 1998-03-25
PE110198A1 (es) 1999-01-21
CA2264941A1 (en) 1998-03-26
HU228178B1 (en) 2013-01-28
EA199900324A1 (ru) 1999-08-26
NO319166B1 (no) 2005-06-27
RS49828B (sr) 2008-08-07
TW541178B (en) 2003-07-11
EP0830864B9 (en) 2003-09-03
ZA977967B (en) 1999-03-04
US6147072A (en) 2000-11-14
KR100532901B1 (ko) 2005-12-02
HUP9903905A2 (hu) 2000-10-28
BR9711530A (pt) 1999-08-24
PL190374B1 (pl) 2005-12-30
PL332481A1 (en) 1999-09-13
HK1009755A1 (en) 1999-06-11
DE69718731D1 (de) 2003-03-06
CA2264941C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
ECSP055885A (es) Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor
ECSP024352A (es) Nueva composicion farmaceutica
AR032086A1 (es) Combinaciones de farmacos
ES2185816T3 (es) Formas de dosificacion farmaceutica para la via oral, que comprenden un agente inhibidor de la bomba de protones y un agente procinetico.
GT200000222A (es) Forma de dosificacion de farmacos accionada por un hidrogel.
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
RS20050392A (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor
CO5251409A1 (es) Combinacion de un inhibidor de la recaptacion de seretonina e irandalona
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
CO5011043A1 (es) Composicion farmaceutica que contiene un compuesto inhibidor ace y estabilizador, tabletas que la contienen y proceso para estabilizar inhibidores de ace
JP2002516282A5 (es)
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
Rubio et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment
PA8523101A1 (es) Composicion de eletriptan en forma de particulas
PA8571901A1 (es) Nueva composicion farmaceutica
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
AR034975A1 (es) Metodo para el tratamiento del insomnio primario
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
TW200507846A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit